Back to basics: PCSK9 as a new target for the LDL receptor
Loading...
Date
2014
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Arquivos brasileiros de cardiologia
Abstract
Description
Forty years after Goldstein and Brown's discovery of the low density lipoprotein receptor (LDLR) and 25 years after the introduction of the statins, a cornerstone of the atherosclerotic disease management, the view of the scientific community studying the process of atherosclerosis turns once again to the LDLR through the action mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9).
The assessment of genetic polymorphism with unexpected results in large studies revived the hypothesis about the important role of high density lipoprotein cholesterol (HDL-C) in lipoprotein metabolism; the apparent eternal debate about the contribution of triglycerides (TG) and their remnants to the phenomenon of atherogenesis. Such advances have lead to the re-prioritization of LDL management as a central and primary objective towards the prevention of the morbidity and mortality main cause in the Western world, atherosclerosis.
Once again, we return to the discovery that led Goldstein and Brown to a Nobel Prize in 1985, the LDLR1; now seeking to avoid its degradation through the knowledge and understanding of PCSK9 action mechanism.
Fil: Corral, Pablo. Universidad FASTA. Facultad de Ciencias MĆ©dicas; Argentina.
Fil: Corral, Pablo. Universidad FASTA. Facultad de Ciencias MĆ©dicas; Argentina.
Keywords
Citation
Corral P. (2014). Back to basics: PCSK9 as a new target for the LDL receptor. Arquivos brasileiros de cardiologia, 102(1), e5āe8. https://doi.org/10.5935/abc.20130248
item.page.issn
1678-4170
item.page.eissn
item.page.isbn
item.page.eisbn
item.page.source
Arquivos brasileiros de cardiologia, 102(1), e5āe8.